{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:06:38Z","timestamp":1778900798244,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignancies from the salivary glands are rare and represent 11% of all cancers from the oropharyngeal anatomical area. Mucoepidermoid Carcinomas (MEC) is the most common malignancy from the salivary glands. Low survival rates of high-grade Mucoepidermoid Carcinomas (MEC) are particularly associated with the presence of positive lymph nodes, extracapsular lymph node spread, and perineural invasion. Most recently, the presence of cancer stem cells (CSC), and the activation of the NF\u03baB signaling pathway have been suggested as cues for an acquired resistance phenotype. We have previously shown that NF\u03baB signaling is very active in MEC tumors. Herein, we explore the efficacy of NF\u03baB inhibition in combination with class I and II HDAC inhibitor to deplete the population of CSC and to destroy MEC tumor cells. Our finding suggests that disruption of NF\u03baB signaling along with the administration of HDAC inhibitors constitute an effective strategy to manage MEC tumors.<\/jats:p>","DOI":"10.1038\/s41598-018-20345-w","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T11:48:02Z","timestamp":1516967282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeting histone deacetylase and NF\u03baB signaling as a novel therapy for Mucoepidermoid Carcinomas"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-2135","authenticated-orcid":false,"given":"Vivian P.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoela D.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A. T.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana O.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy A.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques E.","family":"N\u00f6r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane H.","family":"Squarize","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5358-612X","authenticated-orcid":false,"given":"Rogerio M.","family":"Castilho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"20345_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.critrevonc.2009.10.004","volume":"74","author":"M Guzzo","year":"2010","unstructured":"Guzzo, M. et al. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 74, 134\u2013148 (2010).","journal-title":"Crit Rev Oncol Hematol."},{"key":"20345_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/hed.10400","volume":"26","author":"CH Terhaard","year":"2004","unstructured":"Terhaard, C. H. et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 26, 681\u2013692 (2004).","journal-title":"Head Neck."},{"key":"20345_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.oooo.2012.04.008","volume":"114","author":"FP Fonseca","year":"2012","unstructured":"Fonseca, F. P. et al. Clinicopathologic analysis of 493 cases of salivary gland tumors in a Southern Brazilian population. Oral Surg Oral Med Oral Pathol Oral Radiol. 114, 230\u2013239 (2012).","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"key":"20345_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/hed.2890080309","volume":"8","author":"RH Spiro","year":"1986","unstructured":"Spiro, R. H. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 8, 177\u2013184 (1986).","journal-title":"Head Neck Surg."},{"key":"20345_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.oraloncology.2007.05.010","volume":"44","author":"AV Jones","year":"2008","unstructured":"Jones, A. V., Craig, G. T., Speight, P. M. & Franklin, C. D. The range and demographics of salivary gland tumours diagnosed in a UK population. Oral Oncol. 44, 407\u2013417 (2008).","journal-title":"Oral Oncol."},{"key":"20345_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1217::AID-CNCR2>3.0.CO;2-C","volume":"82","author":"RK Goode","year":"1998","unstructured":"Goode, R. K., Auclair, P. L. & Ellis, G. L. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer. 82, 1217\u20131224 (1998).","journal-title":"Cancer."},{"key":"20345_CR7","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1002\/cncr.26697","volume":"118","author":"CH McHugh","year":"2012","unstructured":"McHugh, C. H. et al. Prognostic factors in mucoepidermoid carcinoma of the salivary glands. Cancer. 118, 3928\u20133936 (2012).","journal-title":"Cancer."},{"key":"20345_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.oraloncology.2012.05.004","volume":"48","author":"A Lagha","year":"2012","unstructured":"Lagha, A. et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers. Oral Oncol. 48, 948\u2013957 (2012).","journal-title":"Oral Oncol."},{"key":"20345_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.critrevonc.2014.02.002","volume":"91","author":"T Cerda","year":"2014","unstructured":"Cerda, T. et al. A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network). Crit Rev Oncol Hematol. 91, 142\u2013158 (2014).","journal-title":"Crit Rev Oncol Hematol."},{"key":"20345_CR10","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.oraloncology.2013.08.004","volume":"49","author":"KA Warner","year":"2013","unstructured":"Warner, K. A. et al. Characterization of tumorigenic cell lines from the recurrence and lymph node metastasis of a human salivary mucoepidermoid carcinoma. Oral Oncol. 49, 1059\u20131066 (2013).","journal-title":"Oral Oncol."},{"key":"20345_CR11","doi-asserted-by":"crossref","first-page":"26633","DOI":"10.18632\/oncotarget.5782","volume":"6","author":"A Adams","year":"2015","unstructured":"Adams, A. et al. ALDH\/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas. Oncotarget. 6, 26633\u201326650 (2015).","journal-title":"Oncotarget."},{"key":"20345_CR12","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1371\/journal.pbio.0020301","volume":"2","author":"TA Venezia","year":"2004","unstructured":"Venezia, T. A. et al. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol. 2, e301 (2004).","journal-title":"PLoS Biol."},{"key":"20345_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2012.07.025","volume":"338","author":"KE Ritchie","year":"2013","unstructured":"Ritchie, K. E. & Nor, J. E. Perivascular stem cell niche in head and neck cancer. Cancer Lett. 338, 41\u201346 (2013).","journal-title":"Cancer Lett."},{"key":"20345_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.med.56.082103.104546","volume":"56","author":"Y Park","year":"2005","unstructured":"Park, Y. & Gerson, S. L. DNA repair defects in stem cell function and aging. Annu Rev Med. 56, 495\u2013508 (2005).","journal-title":"Annu Rev Med."},{"key":"20345_CR15","doi-asserted-by":"publisher","first-page":"e58672","DOI":"10.1371\/journal.pone.0058672","volume":"8","author":"FS Giudice","year":"2013","unstructured":"Giudice, F. S., Pinto, D. S. Jr., Nor, J. E., Squarize, C. H. & Castilho, R. M. Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One. 8, e58672 (2013).","journal-title":"PLoS One."},{"key":"20345_CR16","doi-asserted-by":"crossref","first-page":"42447","DOI":"10.18632\/oncotarget.9884","volume":"7","author":"DM Guimaraes","year":"2016","unstructured":"Guimaraes, D. M. et al. Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells. Oncotarget. 7, 42447\u201342460 (2016).","journal-title":"Oncotarget."},{"key":"20345_CR17","doi-asserted-by":"publisher","first-page":"73032","DOI":"10.18632\/oncotarget.12195","volume":"7","author":"VP Wagner","year":"2016","unstructured":"Wagner, V. P. et al. Overcoming adaptive resistance in mucoepidermoid carcinoma through inhibition of the IKK-beta\/IkappaBalpha\/NFkappaB axis. Oncotarget. 7, 73032\u201373044 (2016).","journal-title":"Oncotarget."},{"key":"20345_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.fob.2013.12.003","volume":"4","author":"LO Almeida","year":"2014","unstructured":"Almeida, L. O. et al. NFkappaB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC). FEBS Open Bio. 4, 96\u2013104 (2014).","journal-title":"FEBS Open Bio."},{"key":"20345_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/499291a","volume":"49","author":"NL Komarova","year":"2013","unstructured":"Komarova, N. L. & Boland, C. R. Cancer: calculated treatment. Nature. 49, 291\u2013292 (2013).","journal-title":"Nature."},{"key":"20345_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LA Diaz Jr.","year":"2012","unstructured":"Diaz, L. A. Jr. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 486, 537\u2013540 (2012).","journal-title":"Nature."},{"key":"20345_CR21","doi-asserted-by":"publisher","first-page":"e00747","DOI":"10.7554\/eLife.00747","volume":"2","author":"I Bozic","year":"2013","unstructured":"Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife. 2, e00747 (2013).","journal-title":"Elife."},{"key":"20345_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature. 441, 431\u2013436 (2006).","journal-title":"Nature."},{"key":"20345_CR23","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1126\/science.274.5288.784","volume":"274","author":"CY Wang","year":"1996","unstructured":"Wang, C. Y., Mayo, M. W. & Baldwin, A. S. Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 274, 784\u2013787 (1996).","journal-title":"Science."},{"key":"20345_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00428-005-1264-9","volume":"446","author":"X Dolcet","year":"2005","unstructured":"Dolcet, X., Llobet, D., Pallares, J. & Matias-Guiu, X. NF-kB in development and progression of human cancer. Virchows Arch. 446, 475\u2013482 (2005).","journal-title":"Virchows Arch."},{"key":"20345_CR25","doi-asserted-by":"publisher","first-page":"e18447","DOI":"10.1371\/journal.pone.0018447","volume":"6","author":"L Wu","year":"2011","unstructured":"Wu, L. et al. IKKbeta regulates the repair of DNA double-strand breaks induced by ionizing radiation in MCF-7 breast cancer cells. PLoS One. 6, e18447 (2011).","journal-title":"PLoS One."},{"key":"20345_CR26","doi-asserted-by":"crossref","unstructured":"Carlson, J. et al. Salivary gland cancer: an update on present and emerging therapies. Am Soc Clin Oncol Educ Book. 257\u2013263 (2013).","DOI":"10.14694\/EdBook_AM.2013.33.257"},{"key":"20345_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/bmj.1.2978.116","volume":"1","author":"AC Lambert","year":"1918","unstructured":"Lambert, A. C. The Treatment of Amoebic Dysentery with Emetine and Bismuth Iodide. Br Med J. 1, 116\u2013118 (1918).","journal-title":"Br Med J."},{"key":"20345_CR28","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.bcp.2009.12.021","volume":"79","author":"SC Miller","year":"2010","unstructured":"Miller, S. C. et al. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol. 79, 1272\u20131280 (2010).","journal-title":"Biochem Pharmacol."},{"key":"20345_CR29","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3892\/or.2013.2838","volume":"31","author":"Y Han","year":"2014","unstructured":"Han, Y. et al. Emetine enhances the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of pancreatic cancer cells by downregulation of myeloid cell leukemia sequence-1 protein. Oncol Rep. 31, 456\u2013462 (2014).","journal-title":"Oncol Rep."},{"key":"20345_CR30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1055\/s-2007-990229","volume":"73","author":"M Moller","year":"2007","unstructured":"Moller, M. & Wink, M. Characteristics of apoptosis induction by the alkaloid emetine in human tumour cell lines. Planta Med. 73, 1389\u20131396 (2007).","journal-title":"Planta Med."},{"key":"20345_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3892\/ijo.2014.2703","volume":"46","author":"Q Sun","year":"2015","unstructured":"Sun, Q., Yogosawa, S., Iizumi, Y., Sakai, T. & Sowa, Y. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL. Int J Oncol. 46, 389\u2013394 (2015).","journal-title":"Int J Oncol."},{"key":"20345_CR32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.juro.2013.09.014","volume":"191","author":"KE Foreman","year":"2014","unstructured":"Foreman, K. E., Jesse, J. N. 3rd, Kuo, P. C. & Gupta, G. N. Emetine dihydrochloride: a novel therapy for bladder cancer. J Urol. 191, 502\u2013509 (2014).","journal-title":"J Urol."},{"key":"20345_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/jcph.486","volume":"55","author":"VS Donnenberg","year":"2015","unstructured":"Donnenberg, V. S. & Donnenberg, A. D. Stem cell state and the epithelial-to-mesenchymal transition: Implications for cancer therapy. J Clin Pharmacol. 55, 603\u2013619 (2015).","journal-title":"J Clin Pharmacol."},{"key":"20345_CR34","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 29, 4741\u20134751 (2010).","journal-title":"Oncogene."},{"key":"20345_CR35","doi-asserted-by":"publisher","first-page":"10464","DOI":"10.1158\/0008-5472.CAN-10-0732","volume":"70","author":"M Liu","year":"2010","unstructured":"Liu, M. et al. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 70, 10464\u201310473 (2010).","journal-title":"Cancer Res."},{"key":"20345_CR36","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R. & Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 12, 1247\u20131252 (2007).","journal-title":"Oncologist."},{"key":"20345_CR37","doi-asserted-by":"publisher","first-page":"11700","DOI":"10.1073\/pnas.182372299","volume":"99","author":"LM Butler","year":"2002","unstructured":"Butler, L. M. et al. The histone deacetylase inhibitor VORINOSTAT arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99, 11700\u201311705 (2002).","journal-title":"Proc Natl Acad Sci USA"},{"key":"20345_CR38","unstructured":"Lee, J. & R, S. H. Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat. Chemotherapy (Los Angel). 2 (2013)."},{"key":"20345_CR39","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1038\/sj.onc.1201867","volume":"16","author":"R Li","year":"1998","unstructured":"Li, R. et al. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene. 16, 3269\u20133277 (1998).","journal-title":"Oncogene."},{"key":"20345_CR40","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1158\/0008-5472.CAN-08-4418","volume":"69","author":"EH Huang","year":"2009","unstructured":"Huang, E. H. et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 69, 3382\u20133389 (2009).","journal-title":"Cancer Res."},{"key":"20345_CR41","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/hed.23076","volume":"35","author":"S Krishnamurthy","year":"2013","unstructured":"Krishnamurthy, S. & Nor, J. E. Orosphere assay: a method for propagation of head and neck cancer stem cells. Head Neck. 35, 1015\u20131021 (2013).","journal-title":"Head Neck."},{"key":"20345_CR42","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 1, 555\u2013567 (2007).","journal-title":"Cell Stem Cell."},{"key":"20345_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.scr.2017.04.003","volume":"21","author":"LO Almeida","year":"2017","unstructured":"Almeida, L. O. et al. Unlocking the chromatin of adenoid cystic carcinomas using HDAC inhibitors sensitize cancer stem cells to cisplatin and induces tumor senescence. Stem Cell Res. 21, 94\u2013105 (2017).","journal-title":"Stem Cell Res."},{"key":"20345_CR44","doi-asserted-by":"crossref","unstructured":"Almeida, L. O., Guimaraes, D. M., Squarize, C. H. & Castilho, R. M. Profiling the Behavior of Distinct Populations of Head and Neck Cancer Stem Cells. Cancers (Basel). 8 (2016).","DOI":"10.3390\/cancers8010007"},{"key":"20345_CR45","first-page":"1","volume":"1","author":"MD Martins","year":"2013","unstructured":"Martins, M. D. & Castilho, R. M. Histones: Controlling Tumor Signaling Circuitry. J Carcinog Mutagen. 1, 1\u201312 (2013).","journal-title":"J Carcinog Mutagen."},{"key":"20345_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mrfmmm.2013.07.002","volume":"750","author":"F Gong","year":"2013","unstructured":"Gong, F. & Miller, K. M. Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. Mutat Res. 750, 23\u201330 (2013).","journal-title":"Mutat Res."},{"key":"20345_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 12, 237\u2013251 (2012).","journal-title":"Nat Rev Cancer."},{"key":"20345_CR48","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348, 994\u20131004 (2003).","journal-title":"N Engl J Med."},{"key":"20345_CR49","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344, 783\u2013792 (2001).","journal-title":"N Engl J Med."},{"key":"20345_CR50","first-page":"1301","volume":"30","author":"C Gridelli","year":"2010","unstructured":"Gridelli, C. et al. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res. 30, 1301\u20131310 (2010).","journal-title":"Anticancer Res."},{"key":"20345_CR51","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/sj.bjc.6690390","volume":"80","author":"GB Baretton","year":"1999","unstructured":"Baretton, G. B., Klenk, U., Diebold, J., Schmeller, N. & L\u00f6hrs, U. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21\/WAF1\/CIP1 expression. Br J Cancer. 80, 546\u201355 (1999).","journal-title":"Br J Cancer."},{"key":"20345_CR52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0304-3835(01)00624-3","volume":"172","author":"TH Cheung","year":"2001","unstructured":"Cheung, T. H. et al. Aberrant expression of p21(WAF1\/CIP1) and p27(KIP1) in cervical carcinoma. Cancer Lett. 172, 93\u20138 (2001).","journal-title":"Cancer Lett."},{"key":"20345_CR53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/(SICI)1097-0045(19990401)39:1<8::AID-PROS2>3.0.CO;2-N","volume":"39","author":"S Aaltomaa","year":"1999","unstructured":"Aaltomaa, S., Lipponen, P., Eskelinen, M., Ala-Opas, M. & Kosma, V. M. Prognostic value and expression of p21(waf1\/cip1) protein in prostate cancer. Prostate. 39, 8\u201315 (1999).","journal-title":"Prostate."},{"key":"20345_CR54","first-page":"1231","volume":"17","author":"G Ferrandina","year":"2000","unstructured":"Ferrandina, G. et al. p21WAF1\/CIP1 protein expression in primary ovarian cancer. Int J Oncol. 17, 1231\u20135 (2000).","journal-title":"Int J Oncol."},{"key":"20345_CR55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nm.2304","volume":"17","author":"H Clevers","year":"2011","unstructured":"Clevers, H. The cancer stem cell: premises, promises and challenges. Nat Med. 17, 313\u2013319 (2011).","journal-title":"Nat Med."},{"key":"20345_CR56","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","volume":"103","author":"W Matsui","year":"2004","unstructured":"Matsui, W. et al. Characterization of clonogenic multiple myeloma cells. Blood. 103, 2332\u20132336 (2004).","journal-title":"Blood."},{"key":"20345_CR57","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1634\/stemcells.2004-0170","volume":"22","author":"L Armstrong","year":"2004","unstructured":"Armstrong, L. et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells. 22, 1142\u201351 (2004).","journal-title":"Stem Cells."},{"key":"20345_CR58","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood-2004-02-0448","volume":"104","author":"DA Hess","year":"2004","unstructured":"Hess, D. A. et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood. 104, 1648\u201355 (2004).","journal-title":"Blood."},{"key":"20345_CR59","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood-2005-06-2284","volume":"107","author":"DA Hess","year":"2006","unstructured":"Hess, D. A. et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood. 107, 2162\u20139 (2006).","journal-title":"Blood."},{"key":"20345_CR60","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1634\/stemcells.2004-0292","volume":"23","author":"DJ Pearce","year":"2005","unstructured":"Pearce, D. J. et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells. 23, 752\u201360 (2005).","journal-title":"Stem Cells."},{"key":"20345_CR61","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.canlet.2013.11.012","volume":"344","author":"ML O\u2019Connor","year":"2014","unstructured":"O\u2019Connor, M. L. et al. Cancer stem cells: A contentious hypothesis now moving forward. Cancer Lett. 344, 180\u20137 (2014).","journal-title":"Cancer Lett."},{"key":"20345_CR62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell. 14, 275\u201391 (2014).","journal-title":"Cell Stem Cell."},{"key":"20345_CR63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature08180","volume":"460","author":"S Yamanaka","year":"2009","unstructured":"Yamanaka, S. Elite and stochastic models for induced pluripotent stem cell generation. Nature. 460, 49\u201352 (2009).","journal-title":"Nature."},{"key":"20345_CR64","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/71750","volume":"24","author":"F Fuks","year":"2000","unstructured":"Fuks, F., Burgers, W. A., Brehm, A., Hughes-Davies, L. & Kouzarides, T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet. 24, 88\u201391 (2000).","journal-title":"Nat Genet."},{"key":"20345_CR65","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature08683","volume":"463","author":"GL Sen","year":"2010","unstructured":"Sen, G. L., Reuter, J. A., Webster, D. E., Zhu, L. & Khavari, P. A. DNMT1 maintains progenitor function in self-renewing somatic tissue. Nature. 463, 563\u2013567 (2010).","journal-title":"Nature."},{"key":"20345_CR66","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3892\/or.2017.5369","volume":"37","author":"W Dong","year":"2017","unstructured":"Dong, W. et al. Exposure to TNF-\u03b1 combined with TGF-\u03b2 induces carcinogenesis in vitro via NF-\u03baB\/Twist axis. Oncol Rep. 37, 1873\u20131882 (2017).","journal-title":"Oncol Rep."},{"key":"20345_CR67","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/his.13218","volume":"71","author":"LP Webber","year":"2017","unstructured":"Webber, L. P. et al. Hypoacetylation of acetyl-histone H3 (H3K9ac) as marker of poor prognosis in oral cancer. Histopathology. 71, 278\u2013286 (2017).","journal-title":"Histopathology."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20345-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20345-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20345-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:42:48Z","timestamp":1671586968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20345-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["20345"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-20345-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"9 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2065"}}